May. 27 at 12:10 PM
BofA reiterated
$MLYS Buy-
$38 and said, "On Saturday at the European Meeting on Hypertension and Cardiovascular Protection (ESH), Mineralys (
$MLYS ) shared full data from its Ph 3 Launch-HTN trial with lorundrostat (lor) in uncontrolled/resistant hypertension (u/rHTN)."
$AZN $NVS $LLY
BofA added, "Recall this trial represents a "real world setting", where patients were allowed to stay on their existing background therapy. Overall, there were no surprises vs what was already shared with the topline release (see
$MLYS: Strong phase 3 data - from here, benefits most if it finds a partner) and full Advance-HTN data at ACC/NEJM publication (
$MLYS: Advance-HTN update at ACC suggests lorundrostat is commercially relevant).
In our view, the Launch-HTN data are consistent with Advance-HTN and continue to support approval and a commercially relevant profile.
BofA additionally said:
